title: Real world clinical performance of the zotarolimus eluting coronary stent system in Chinese patients: a prospective, multicenter registry study.
abstract: BACKGROUND
  Early clinical trials with the Endeavor zotarolimus eluting stent (ZES) in western populations demonstrated low rates of target lesion revascularization with a favorable safety profile including low late stent thrombosis with up to 5 years of follow-up. The aim of this clinical registry study was to evaluate real world clinical performance of the ZES coronary system in Chinese patients.
  
  
  METHODS
  The China Endeavor Registry is a prospective, multicenter registry assessing the safety of the ZES system in a real world patient population. It was conducted at 46 centers in China in routine treatment of patients with coronary artery stenosis, including patients with clinical characteristics or lesion types that are often excluded from randomized controlled trials. The registry included 2210 adult patients who underwent single-vessel or multi-vessel percutaneous coronary intervention. The primary end point was the rate of major adverse cardiac events (MACE) at 12 months.
  
  
  RESULTS
  The 12-month rate of MACE for all patients in the registry was 3.03%. Cardiac death or myocardial infarction rate was 1.28% and target lesion revascularization rate was 1.66%, non-target lesion target vessel revascularization (TVR) was 0.52%, TVR was 2.18%, and target vessel failure was 3.22%. There was only one case of emergent cardiac bypass surgery. The 12-month overall incidence of all Academic Research Consortium (ARC)-defined stent thrombosis was 0.43%.
  
  
  CONCLUSIONS
  Mid-term results from the real-world China Endeavor Registry suggest that Endeavor ZES was safe and effective in Chinese patients.
authors.affiliation: Department of Cardiology, Institute of Cardiovascular Research of People's Liberation Army, Shenyang Northern Hospital, Shenyang, Liaoning 110840, China. hanyaling@263.net
authors.forename: Ya-Ling
authors.initials: YL
authors.lastname: Han
authors.forename: Ji-Yan
authors.initials: JY
authors.lastname: Chen
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.forename: Hong-Bing
authors.initials: HB
authors.lastname: Yan
authors.forename: Le-Feng
authors.initials: LF
authors.lastname: Wang
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Li
authors.forename: Hong-Liang
authors.initials: HL
authors.lastname: Cong
authors.forename: Quan-Min
authors.initials: QM
authors.lastname: Jing
authors.forename: Shou-Li
authors.initials: SL
authors.lastname: Wang
authors.forename: Kai
authors.initials: K
authors.lastname: Xu
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Huo
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D044466:Asian People; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: C489443:zotarolimus; D020123:Sirolimus